EE03017B1 - Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks - Google Patents

Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks

Info

Publication number
EE03017B1
EE03017B1 EE9400003A EE9400003A EE03017B1 EE 03017 B1 EE03017 B1 EE 03017B1 EE 9400003 A EE9400003 A EE 9400003A EE 9400003 A EE9400003 A EE 9400003A EE 03017 B1 EE03017 B1 EE 03017B1
Authority
EE
Estonia
Prior art keywords
concentrate
specific activity
high specific
therapeutic use
preparation
Prior art date
Application number
EE9400003A
Other languages
English (en)
Estonian (et)
Inventor
Burnouf Miryana
Dernis Dominique
Original Assignee
Association pour l'Essor de la Transfusion Sanguine dans la R�gion du Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association pour l'Essor de la Transfusion Sanguine dans la R�gion du Nord filed Critical Association pour l'Essor de la Transfusion Sanguine dans la R�gion du Nord
Publication of EE03017B1 publication Critical patent/EE03017B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6443Coagulation factor XIa (3.4.21.27)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21027Coagulation factor XIa (3.4.21.27)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EE9400003A 1991-05-07 1994-05-23 Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks EE03017B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9105572A FR2676231A1 (fr) 1991-05-07 1991-05-07 Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.

Publications (1)

Publication Number Publication Date
EE03017B1 true EE03017B1 (et) 1997-08-15

Family

ID=9412593

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400003A EE03017B1 (et) 1991-05-07 1994-05-23 Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks

Country Status (16)

Country Link
US (1) US5252217A (lt)
EP (1) EP0512883B1 (lt)
AT (1) ATE156360T1 (lt)
AU (1) AU652043B2 (lt)
BR (1) BR9201718A (lt)
CA (1) CA2068069C (lt)
DE (1) DE69221369T2 (lt)
DK (1) DK0512883T3 (lt)
EE (1) EE03017B1 (lt)
ES (1) ES2107511T3 (lt)
FR (1) FR2676231A1 (lt)
GR (1) GR3025134T3 (lt)
IL (1) IL99567A (lt)
LT (1) LT3417B (lt)
RU (1) RU2097047C1 (lt)
UA (1) UA27733C2 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
CZ200439A3 (cs) * 2001-07-20 2005-03-16 Novo Nordisk A/S Farmaceutický prostředek obsahující polypeptidy faktoru Vll a polypeptidy faktoru XI
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
KR20060118486A (ko) * 2003-11-20 2006-11-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 xi의 치료적 사용
WO2006128497A1 (en) * 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
AU2007292253A1 (en) * 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
US20100062512A1 (en) * 2007-01-04 2010-03-11 Crucell Holland B.V. Purification of factor xi
MX2011004097A (es) * 2008-10-15 2011-07-28 Isis Pharmaceuticals Inc Modulacion de la expresion del factor 11.
FR2974366B1 (fr) * 2011-04-20 2016-06-24 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur xi
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
IL212911A0 (en) 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
DE102012022233A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Verfahren zur Reinigung eines (Blut)plasmaproteins
DE102012022234A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Einstufiges Verfahren zur Reinigung von (Blut)Plasmaproteinen wie Albumin aus Gemischen
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
MX2020011913A (es) 2018-05-09 2021-01-29 Ionis Pharmaceuticals Inc Compuestos y metodos para la reduccion de la expresion de fxi.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859340A (en) * 1976-03-15 1989-08-22 Cuno, Incorporated Filter sheet
US4783262A (en) * 1987-03-30 1988-11-08 Cuno Incorporated Separator for cell type filter element

Also Published As

Publication number Publication date
IL99567A (en) 1996-01-19
LT3417B (en) 1995-09-25
ES2107511T3 (es) 1997-12-01
AU652043B2 (en) 1994-08-11
EP0512883B1 (fr) 1997-08-06
GR3025134T3 (en) 1998-02-27
LTIP265A (en) 1994-10-25
DE69221369T2 (de) 1998-03-19
FR2676231A1 (fr) 1992-11-13
UA27733C2 (uk) 2000-10-16
FR2676231B1 (lt) 1995-04-21
CA2068069A1 (en) 1992-11-08
EP0512883A1 (fr) 1992-11-11
CA2068069C (en) 2005-03-15
US5252217A (en) 1993-10-12
DK0512883T3 (da) 1998-03-16
ATE156360T1 (de) 1997-08-15
IL99567A0 (en) 1992-08-18
AU1526392A (en) 1992-11-12
BR9201718A (pt) 1992-12-29
DE69221369D1 (de) 1997-09-11
RU2097047C1 (ru) 1997-11-27

Similar Documents

Publication Publication Date Title
EE03017B1 (et) Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks
EP0787802A3 (lt)
NO880022L (no) Fremstilling av m-csf.
ZA863133B (en) Therapeutical application of phosphonylmethoxyalkyl adenines
IT1219874B (it) Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
DE3782498D1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
ATE97813T1 (de) Mittel zur kontrolle von thrombenbildungen.
FI875319A (fi) Bisyklisten aminokarboksyylihappojen johdannaiset, menetelmä niiden valmistamiseksi ja niiden valmistuksessa käytettävät välituotteet, sekä niiden käyttö
AU7426487A (en) Method of treating depression using d-fenfluramine
AU6110490A (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
EP0388799A3 (en) Use of human interferon-beta for stimulation of erythropoieses
IT8647591A0 (it) Procedimento per la tintura in sezione delle pelli
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
EP0212310A3 (en) Use of probucol in the preparation of a medicament for the treatment of heart arrhythmia
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
RO82337A2 (ro) Bomboane medicinale pentru tratamentul afectiunilor buco-faringiene la copii
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DK0385422T3 (da) 1,4-Dihydro-5-isopropoxy-2-methyl-4-(2-trifluormethylphenyl)-1,6-naphthyridin-3-carboxylsyre-(-(N-methyl-N-phenylmethylamino)ethyl)ester-fumarat
RU94031049A (ru) Способ лечения дисфункциональных расстройств организма человека
DE58901297D1 (de) Noremopamil, seine herstellung und verwendung.
BR8702799A (pt) Aparelho e metodo biomedicos para controlar a administracao de terapia a um paciente em resposta a mudancas na demanda fisiologica

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20100523